Why Am I Not Losing Weight on Semaglutide or Tirzepatide? The Plateau and Non-Responder Guide

“Why am I not losing weight on semaglutide?” is a high-volume patient search (~1,400/mo) for a reason: the STEP-1 trial reported that roughly 14% of participants on semaglutide 2.4 mg lost less than 5% of body weight over 68 weeks [1], and SURMOUNT-1 reported that roughly 9% of tirzepatide 15 mg participants fell into the same bucket [2]. Non-response is real, documented, and distinct from the much larger group of patients who think they're non-responders but are actually in one of three addressable states: early-titration (dose hasn't reached full effect), technical error (dose math or injection technique is silently reducing absorption), or the natural late-trial plateau that almost every successful responder hits around week 40-60. This guide walks through each bucket with the specific fix.

The three buckets — and how to tell which one you're in

1. Early-titration “not yet” (weeks 1-16). Most patients who feel they're not responding in the first 3-4 months are in this bucket. The dose has simply not reached its full pharmacokinetic effect yet. See the week-by-week expected weight loss curve in our how long does GLP-1 take to work guide. If you're at week 8 and frustrated that you've only lost 3%, that's actually on the STEP-1 trial curve and the next 12 weeks are the steepest-loss window.
2. Technical error (any time). A silent error in dose math or injection technique can reduce absorption by 25-50% without producing any visible sign [4]. This is the most fixable bucket and also the most common overlooked cause. Fix it and the weight loss resumes.
3. Trial-curve plateau (weeks 40-68). After week 40 on semaglutide or week 52 on tirzepatide, the weight loss curve naturally flattens. If you're at week 50 and you've already lost 13% but the scale hasn't moved for a month, you're hitting the same plateau almost every successful responder hits in the STEP and SURMOUNT curves [1, 2]. This is not failure — it's the shape of the curve.

Bucket 1: Early-titration non-response

The STEP-1 weight loss curve at weeks 4, 12, 20, and 28 (verified from the trial publication [1]):

If you're at or above the trial curve numbers for your week, you are not a non-responder. If you're below, check bucket 2 before concluding anything.

Bucket 2: Technical error in dose or injection

This is the most fixable and most under-appreciated bucket. Three specific errors account for almost all silent under-dosing:

Error 1: Wrong unit count on a compounded vial

Compounded GLP-1 vials are dosed in insulin syringe units, and the mg-to-units conversion depends on the vial concentration. A 2.5 mg/mL semaglutide vial at “20 units” delivers 0.5 mg. A 5 mg/mL vial at the same 20 units delivers 1.0 mg. Patients who switch between pharmacies or concentrations frequently end up on the wrong unit count for their new vial and effectively halve or double their dose without realizing. Use our GLP-1 unit converter to verify your current math against the concentration printed on your vial label.

Error 2: Injecting into lipohypertrophy

Repeated injection into the same small patch of subcutaneous tissue produces lipohypertrophy — firm fatty nodules that absorb injected drug 25-50% slower than normal tissue [4]. The most common patient error is returning to the same “favorite” spot because it hurts less, which is actually the early sign of lipohypertrophy. Fix: rotate sites every injection, at least 1 inch from the last one. See our injection technique guide for the recommended rotation pattern.

Error 3: Wrong-dose pen

For brand-name Wegovy and Ozempic pens, each pen delivers a specific fixed dose. Patients occasionally end up with a starter-dose pen (0.25 mg) when they should be on a maintenance pen (2.4 mg) and the pharmacy tech or the telehealth prescriber made a dispensing error. Check the dose printed on the pen label against your prescribed dose at every pickup.

Bucket 3: The trial-curve plateau

Look at the STEP-1 and SURMOUNT-1 curves past week 40 [1, 2]. The rate of weight loss slows progressively:

The curves are not linear. Between weeks 28 and 68 of STEP-1, the average participant lost only 3 additional percentage points — compared to the 12 points they lost in weeks 0-28. That's the natural shape, not a signal that the drug stopped working. The STEP-4 extension trial [3] confirmed that patients who continued on semaglutide past week 20 maintained the loss, while patients who stopped regained weight rapidly. The maintenance effect is real; it just doesn't produce continuing dramatic loss.

What to actually do when the scale stops moving

A prioritized action plan for any patient who thinks they've hit a plateau or non-response:

1. Confirm your week number against the trial curve. If you're below week 16, you're probably not non-responding — you're early. Wait until week 20-24 to judge.
2. Verify your dose math. Pull out your vial label, check the concentration, and recompute the units you should be drawing using our unit converter. This catches ~30% of “plateaus” in practice.
3. Examine your injection site. Feel for firm nodules. If you find any, stop using that site for 6-8 weeks and rotate to fresh tissue. Absorption from the new site is usually normal.
4. Verify you're on the maintenance dose. Wegovy maintenance is 2.4 mg. Zepbound maintenance is 15 mg. If you're not at maintenance yet, the conversation is about completing titration, not about plateau.
5. Track body composition, not just body weight. During the late-trial plateau, body composition often improves (lean mass up, fat mass down) even when total body weight is flat. Waist circumference is the cheapest proxy; body composition testing is more precise.
6. Review protein intake and resistance training. If you're losing muscle, the scale can stay flat even as you add fat — a bad outcome. See our muscle mass deep-dive.
7. Discuss drug switching with your prescriber. Tirzepatide produces larger weight loss than semaglutide in head-to-head comparisons [2]. If you're on semaglutide and have truly plateaued at maintenance dose with verified correct technique, switching to tirzepatide is an evidence-based next step.

When to consider stopping

The STEP-4 trial [3] is the key reference for the discontinuation decision. Patients who stopped semaglutide at week 20 regained roughly 67% of their lost weight within one year. This is not a failure of willpower — it's a documented physiological rebound driven by the same appetite and energy-expenditure mechanisms the drug was suppressing. Before deciding to discontinue:

• Understand that GLP-1 therapy for obesity is a chronic disease therapy, not a course of treatment. The trial evidence does not support short- course use followed by drug-free maintenance.
• See our what happens when you stop semaglutide deep-dive for the full STEP-4 data and the expected rebound timeline.
• Discuss alternative drug options with your prescriber before discontinuing — switching is almost always a better option than stopping.

Related research and tools

For the verified trial-curve timing, see our how long does GLP-1 take to work guide. For the injection technique pattern that prevents absorption loss, see our injection guide. For the dose math, use our unit converter. For the discontinuation rebound data, see our post-discontinuation deep-dive. For the head-to-head that supports switching from semaglutide to tirzepatide, see our head-to-head comparison.